Bibliography
- World Health Organization. Depression: what is depression? Available from: http://www.who.int/mental_health/management/depression/definition/en/ [Last accessed 14 August 2009]
- Antidepressant Market. Available from: http://www.wikinvest.com/concept/Antidepressant_Drug_Market [Last accessed 17 August 2009]
- Bourin M, Chue P, Guillon Y. Paroxetine: a review. CNS Drug Rev 2001;7:25-47
- Pae CU, Patkar AA. Paroxetine: current status in psychiatry. Expert Rev Neurother 2007;7:107-20
- GlaxoSmithKline. GSK annual report 2008. Available from: http://www.gsk.com/investors/reps08/GSK-Report-2008-full.pdf [Last accessed 14 August 2009]
- Center for Drug Evaluation and Research. Medical Review. Application Number 21-299. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist [Last accessed 30 July 2009]
- Center for Drug Evaluation and Research. Clinical Pharmacology and Biopharmaceutics Review. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-299.pdf_Paroxetine%20Mesylate_BioPharmr.pdfAccess [Last accessed 21 July 2009]
- Noven Therapeutics I. Prescribing information. Paroxetine Mesylate (Pexeva). Available from: http://www.pexeva.com/ [Last accessed 21 July 2009]
- Kaye CM, Haddock RE, Langley PF, A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr Scand Suppl 1989;350:60-75
- Gunasekara NS, Noble S, Benfield P. Paroxetine. An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders. Drugs 1998;55:85-120
- Wagstaff AJ, Cheer SM, Matheson AJ, Paroxetine: an update of its use in psychiatric disorders in adults. Drugs 2002;62:655-703
- Einarson A, Koren G. Counseling pregnant women treated with paroxetine. Concern about cardiac malformations. Can Fam Physician 2006;52:593-4
- Center for Drug Evaluation and Research. Pharmacology Review. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-299.pdf_Paroxetine%20Mesylate_Pharmr.pdf [Last accessed 21 July 2009]
- Owens MJ, Krulewicz S, Simon JS, Estimates of serotonin and norepinephrine transporter inhibition in depressed patients treated with paroxetine or venlafaxine. Neuropsychopharmacology 2008;33:3201-3212
- Owens MJ, Nemeroff CB. Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin Chem 1994;40:288-95
- Bang LM, Keating GM. Paroxetine controlled release. CNS Drugs 2004;18:355-64; discussion 65-6
- Thomas DR, Nelson DR, Johnson AM. Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor. Psychopharmacology (Berl) 1987;93:193-200
- Marks DM, Park MH, Ham BJ, Paroxetine: safety and tolerability issues. Expert Opin Drug Saf 2008;7:783-94
- GlaxoSmithKline. Paxil. 2006. Available from: http://www.gsk.com [Last accessed 15 July 2009]
- GlaxoSmithKline. Paxil CR. 2006. Available from: http://www.gsk.com [Last accessed 15 July 2009]
- Rosenthal J, Kong B, Jacobs L, Katzman M. Did a switch to a generic antidepressant cause relapse? J Fam Pract 2008;57:109-14
- Vergouwen AC, Bakker A. Adverse effects after switching to a different generic form of paroxetine: paroxetine mesylate instead of paroxetine HCl hemihydrate. Ned Tijdschr Geneeskd 2002;146:811-12
- Borgheini G. The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs. Clin Ther 2003;25:1578-92
- Meyer MC. United States Food and Drug Administration requirements for approval of generic drug products. J Clin Psychiatry 2001;62(Suppl 5):4-9, discussion 23-4
- Korean Food and Drug Administration. Available from: http://kfda.go.kr/open_content/data/law_search.php [Last accessed 29 August 2009]
- Sheehan DV, Keene MS, Eaddy M, Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disorders. CNS Drugs 2008;22:963-73
- Jonsdottir H, Friis S, Horne R, Beliefs about medications: measurement and relationship to adherence in patients with severe mental disorders. Acta Psychiatr Scand 2009;119:78-84
- Kessler RC, Chiu WT, Demler O, Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:617-27
- Kessler RC, Berglund P, Demler O, The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289:3095-105
- Mofsen R, Balter J. Case reports of the reemergence of psychotic symptoms after conversion from brand-name clozapine to a generic formulation. Clin Ther 2001;23:1720-31
- Lam YW, Ereshefsky L, Toney GB, Gonzales C. Branded versus generic clozapine: bioavailability comparison and interchangeability issues. J Clin Psychiatry 2001;62(Suppl 5):18-22, discussion 3-4
- Ereshefsky L, Glazer WM. Comparison of the bioequivalence of generic versus branded clozapine. J Clin Psychiatry 2001;62:(Suppl 5):25-7
- Locniskar A, Greenblatt DJ, Harmatz JS, Shader RI. Bioinequivalence of a generic brand of diazepam. Biopharm Drug Dispos 1989;10:597-605
- Mikati M, Bassett N, Schachter S. Double-blind randomized study comparing brand-name and generic phenytoin monotherapy. Epilepsia 1992;33:359-65
- Welty TE, Pickering PR, Hale BC, Arazi R. Loss of seizure control associated with generic substitution of carbamazepine. Ann Pharmacother 1992;26:775-7
- Berg MJ, Gross RA, Tomaszewski KJ, Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures. Neurology 2008;71:525-30
- Dhanaraj M, Jayavelu A. Non-equivalence of bioavailability between generic and branded form of sodium valproate. Neurol India 2004;52:398
- Sherwood Brown E, Shellhorn E, Suppes T. Gastrointestinal side-effects after switch to generic valproic acid. Pharmacopsychiatry 1998;31:114
- MacDonald JT. Breakthrough seizure following substitution of Depakene capsules (Abbott) with a generic product. Neurology 1987;37:1885
- Gidal BE. Bioequivalence of antiepileptic drugs: how close is close enough? Curr Neurol Neurosci Rep 2009;9:333-7
- Wilner AN. Therapeutic equivalency of generic antiepileptic drugs: results of a survey. Epilepsy Behav 2004;5:995-8
- Bakish D, Miller C, Hooper CL, A double-blind, crossover study comparing generic and brand fluoxetine in the treatment of major depressive disorder. NCDEU, 2001
- Yu BP, Chong YS, Maguire GA. Is generic fluoxetine effective? J Affect Disord 2004;81:185-6
- Van Ameringen M, Mancini C, Patterson B, Bennett M. Symptom relapse following switch from Celexa to generic citalopram: an anxiety disorders case series. J Psychopharmacol 2007;21:472-6
- Center for Drug Evaluation and Research. Review of therapeutic equivalence: generic bupropion XL 300 mg and Wellbutrin XL 300 mg. US Food and Drug Administration. Available from: http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm153270.htm [Last accessed 20 August]
- Chenu F, Batten LA, Zernig G, Comparison of pharmacokinetic profiles of brand-name and generic formulations of citalopram and venlafaxine: a crossover study. J Clin Psychiatry 2009;70:958-66
- Byrne SE, Rothschild AJ. Loss of antidepressant efficacy during maintenance therapy: possible mechanisms and treatments. J Clin Psychiatry 1998;59:279-88
- Rush AJ, Trivedi MH, Wisniewski SR, Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006;163:1905-17
- Dotoli D, Spagnolo C, Bongiorno F, Relapse during a 6-month continuation treatment with fluvoxamine in an Italian population: the role of clinical, psychosocial and genetic variables. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:442-8
- Keller MB, Trivedi MH, Thase ME, The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the 2-year and combined maintenance phases. J Clin Psychiatry 2007;68:1246-56
- Paton C. Generic clozapine: outcomes after switching formulations. Br J Psychiatry 2006;189:184-5
- Healy DJ, Taylor S, Goldman M, Clinical equivalence of generic clozapine. Community Ment Health J 2005;41:393-8
- Alessi-Severini S, Honcharik PL, Simpson KD, Evaluation of an interchangeability switch in patients treated with clozapine: a retrospective review. J Clin Psychiatry 2006;67:1047-54
- Jefferson JW. Antidepressants: brand name or generic? Psychiatric Times 2009;26